Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 development
OXFORD, United Kingdom and BURLINGTON, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP) (“ Scancell ”, or the “ Company ”), a late-stage clinical immuno-oncology company developing active immunotherapies designed to enhance anti-tumor immune responses in difficult-to-treat cancers, announced today that, further to its announcement on 23 July 2026 regarding the planned merger with Neuphoria Therapeutics Inc. (“ Neuphoria ”) and financing to conduct the registrational Phase 3 study for iSCIB1+ and a proposed listing on Nasdaq (the “ Merger and Financing Announcement ”), it has entered into a loan agreement (the “ Loan Agreement ”) with certain funds and accounts managed by BlackRock (the “ Lender ”), for a loan facility of up to US$25,000,000 (the “ Loan Facility” ).